Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05501002
Other study ID # CLIN-0029
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 15, 2022
Est. completion date September 15, 2023

Study information

Verified date February 2024
Source CereVasc Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. The eShunt® Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.


Description:

This is a prospective, multi-center, open label, pilot study of the eShunt® System. The study population consists of patients with post-aneurysmal subarachnoid hemorrhage (SAH) treated for increased intracranial pressure (ICP) resulting in symptomatic hydrocephalus using an external ventricular drain (EVD) to facilitate CSF drainage and who cannot be "weaned" from the EVD after the hemorrhagic event. After completion of the procedure to place the eShunt® device, the ICP will be monitored and recorded for up to 48 hours. Subjects will then return for follow-up visits that include standard neurological evaluations at 30, 60, 90, 180, and 365 days postimplantation; imaging will also be acquired at 30, 90 and 365 days after implant. Subjects will continue to attend follow-up visits every 180 days thereafter until the study is closed or up to 5 years post-implantation.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date September 15, 2023
Est. primary completion date September 15, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Patient is = 21 years old - Patient or legally authorized representative is able and willing to provide written informed consent - Post-aneurysmal SAH with Hunt and Hess Grades I-IV with EVD in place for at least 7 days with the need for a permanent CSF shunt determined through a failed EVD clamping trial defined as: 1. Post-clamping ICP of > 20 cmH2O for 15 minutes, or 2. Post-clamping ICP > 25 cmH2O for < 15 minutes with patient intolerance to EVD clamping, or 3. Significant radiographic signs of increasing ventriculomegaly, or 4. Neurological decline attributable to ventriculomegaly and requiring CSF diversion - Clinical signs and symptoms of communicating hydrocephalus - Neurologically stable without evidence of severe vasospasm - Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by subject screening committee (SSC) - Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC Exclusion Criteria: - Presence of gross blood in CSF - Signs or symptoms of obstructive hydrocephalus - Active systemic infection or infection detected in CSF - Prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus - Hypersensitivity or contraindication to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available - Occlusion or stenosis of the internal jugular vein - Venous distension in the neck on physical exam - Medical conditions associated with prolonged elevation of jugular venous pressure, including jugular vein stenosis or stricture, right sided heart failure, cirrhosis of the liver, arterial venous fistulas in the arm for dialysis purposes, or an arterial venous fistula or malformation in the neck or brain - Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram - History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency - Stroke or transient ischemic attack within 180 days of eShunt Procedure - Presence of a deep vein thrombosis superior to the popliteal vein - International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 seconds) - Presence of a posterior fossa tumor or mass - Life expectancy < 1 year - Currently participating in another investigational drug or device trial that could conflict with study data collection or follow-up - Pregnant - Unwilling or unable to comply with follow-up requirements

Study Design


Related Conditions & MeSH terms


Intervention

Device:
eShunt® Implant
The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.

Locations

Country Name City State
United States Yale University New Haven Connecticut
United States Montefiore Medical Center Department of Neurosurgery New York New York

Sponsors (4)

Lead Sponsor Collaborator
CereVasc Inc AlvaMed, Inc., Bioscience Consulting, Inc., Simplified Clinical Data Systems, LLC

Country where clinical trial is conducted

United States, 

References & Publications (2)

Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9. — View Citation

Lylyk P, Lylyk I, Bleise C, Scrivano E, Lylyk PN, Beneduce B, Heilman CB, Malek AM. First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt. J Neurointerv Surg. 2022 May;14(5):495-9. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction in ICP At 24 to 48 hours after eShunt Implant deployment (with EVD remaining clamped) an ICP measurement that indicates:
ICP below 20 cmH2O with no periods longer than 15 minutes above 20 cmH2O
No episodes of ICP above 25 cmH2O with associated symptoms
24-48 hours after eShunt Implant placement
Secondary Occurrence of Serious Adverse Events The number of device and/or procedure-related serious adverse events (SAEs) after the implant procedure will be calculated. 90 days post procedure
Secondary Incidence of clinically significant changes in Computed Tomography Imaging (CT/CTA) from baseline. Clinically significant changes from baseline CT images will be summarized 1 year post procedure
Secondary Number of participants with clinically significant changes in physical and neurologic examination assessments from baseline Clinically significant changes from baseline physical examination and neurologic examination assessments will be summarized 1 year post procedure
Secondary Summary of Adverse Events Tabulation of all Adverse Events collected in the study. 90 days post procedure and at study completion
Secondary Changes in Modified Rankin Scale Scores Changes in Modified Rankin Scale scores from baseline will be summarized. 1 year post procedure
Secondary Number of subjects requiring conversion to conventional CSF shunt Evaluate the need for CSF diversion by conventional CSF shunt insertion within 12 months after eShunt Implant deployment 1 year post procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06040697 - Formative Usability Assessment of Wireless Thermal Anisotropy Devices
Terminated NCT02408757 - Sonographic Monitoring of Weaning of Cerebrospinal Fluid Drainages
Terminated NCT01863381 - Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement N/A
Completed NCT00652470 - A Study Comparing Two Treatments for Infants With Hydrocephalus Phase 2
Completed NCT00196196 - A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System. Phase 3
Active, not recruiting NCT05068128 - Combined Flow and Pressure Study of Craniospinal Dynamic
Completed NCT04496414 - Bactiseal Catheter Safety Registry in China
Terminated NCT02900222 - Study of Choroid Plexus Cauterization in Patients With Hydrocephalus N/A
Recruiting NCT04099823 - MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics N/A
Unknown status NCT02775136 - An Evaluation of a Non-invasive Brain Monitor N/A
Completed NCT00692744 - Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH) N/A
Recruiting NCT04758611 - The ETCHES I Study (Endovascular Treatment of Communicating Hydrocephalus With an Endovascular Shunt) N/A
Completed NCT03595033 - Hydrocephalus iPad-App Based Intervention Study N/A
Completed NCT04207229 - CERTAS Programmable Valve Registry
Completed NCT01976559 - Comparison of Continuous Noninvasive and Invasive Intracranial Pressure Measurement--Celda Infusion Subprotocol N/A
Terminated NCT01973764 - Intraventricular Drain Insertion: Comparison of Ultrasound-guided and Landmark-based Puncture of the Ventricular System N/A
Completed NCT02381977 - Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment N/A
Recruiting NCT06086561 - Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device N/A
Recruiting NCT05910944 - European Study of Prodromal iNPH
Recruiting NCT03650101 - Improving Infant Hydrocephalus Outcomes in Uganda